¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2022³â ´ëÇѹÙÀÌ·¯½ºÇÐȸ Á¤±âÇмú´ëȸ : 2022-08-27

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2022³â ´ëÇѹÙÀÌ·¯½ºÇÐȸ Á¤±âÇмú´ëȸ : 2022-08-27
±³À°ÀÏÀÚ : 2022-08-27
±³À°Àå¼Ò : À»ÁöÀη°³¹ß¿ø  
±³À°ÁÖÁ¦ : 2022³â ´ëÇѹÙÀÌ·¯½ºÇÐȸ Á¤±âÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѹÙÀÌ·¯½ºÇÐȸ
´ã´çÀÚ : ÃÖ¼¼ÀÎ
¿¬¶ôó : 070-8886-3062  
À̸ÞÀÏ : virology@ksov.org      
±³À°Á¾·ù : ÀÇ»çÇйýÀÇÇп¹¹æÀÇÇÐÇغÎÇлý¸®ÇлýÈ­ÇкÐÀÚ»ý¹°Çй̻ý¹°Çбâ»ýÃæÇоฮÇР     
Âü¼®¿¹»óÀοø : 250¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : °­¿øµµ
±³À°½Ã°£ : 5 ½Ã°£ 5ºÐ  
¼¼ºÎ¼ö°­·á : 200,000¿ø      
ºñ°í ÆòÀÇ¿ø: ÀÏ¹Ý 20¸¸¿ø, Çлý 8¸¸¿ø Á¤È¸¿ø: ÀÏ¹Ý 15¸¸¿ø, Çлý 8¸¸¿ø ºñȸ¿ø: ÀÏ¹Ý 15¸¸¿ø, Çлý 8¸¸¿ø ÇöÀåµî·Ï: ÀÏ¹Ý 20¸¸¿ø, Çлý 10¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ09:30~09:50 Modeling how peginterferon alfa improves clearance rates of cccDNA in hepatitis B virus infected patients  ±è±¤¼ö(ºÎ°æ´ëÇб³ °úÇнýºÅ۽ùķ¹À̼ÇÇаú) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ09:50~10:10 Antiviral activity of activated cdc42-associated kinase 1 against hepatitis B virus  ¹Ú¿ë±¤(±¹¸³º¸°Ç¿ø ¸¸¼º¹ÙÀÌ·¯½º¿¬±¸°ú) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ10:10~10:30 Role of p62/SQSTM1 in ZIKV Pathogenesis  ±è¼ºÁØ(Çѱ¹È­Çבּ¸¿ø) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ10:30~10:45 SARS-CoV-2 productively infects human hepatocytes and induces cell death  °íõ±Ô(Çѱ¹È­Çבּ¸¿ø) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ10:45~11:00 Host sensing of RNA viruses and the viral evasion strategies: From fundamental mechanism study to the development of the screening tool  À¯Áö½Â(±âÃÊ°úÇבּ¸¿ø Çѱ¹¹ÙÀÌ·¯½º±âÃÊ¿¬±¸¼Ò) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ11:00~11:15 CaMKII Inhibits HBV Replication via AMPK/AKT/mTOR Signaling pathways  ±èÁÖ¹Ì(¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ11:15~11:30 The regulatory T cell population is not normalized following successfultreatment of chronic hepatitis C with direct-acting antivirals  ±è¼Ò¿µ(KAIST) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ13:05~13:30 Viral G-quadruplex as a promising target to control SARS-CoV-2 infection  ¼Û¹®Á¤(°í·Á´ëÇб³ »ý¸í°úÇдëÇÐ) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ13:30~13:55 Preparedness against Viral Disease X with active surveillance from wild life animals and nanobiotechnology for diagnosis, antiviral, and vaccine  ¼Û´ë¼·(¼­¿ï´ëÇб³ ¼öÀÇ°ú´ëÇÐ) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ13:55~14:20 Influenza and SARS-CoV-2 co-infection alters viral tropism in Syrian hamsters  À±¼±¿ì(Çѱ¹»ý¸í°øÇבּ¸¿ø) 
Åä·Ð 08-27 ´ë°­ÀǽǠ14:20~14:40 ÁúÀÇÀÀ´ä  () 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ14:40~14:52 SARS-CoV-2 omicron mainly utilizes cathepsin for infectivity and fusogenicity  ÀåÀǼø(°í·Á´ëÇб³ »ý¸íÁ¤º¸Çаú) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ14:52~15:04 Definition and correlation analysis of bimodal distribution of sequencing data of transcriptome and chromatin accessibility  ±è±¤ÈÆ(¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ15:04~15:16 Single Cell Transcriptomic Analysis of Human Lung Organoids to model SARS-CoV-2 Infection  À̼¼À±(¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ15:16~15:28 Aging dependent Immunopathology of the COVID-19 : The potent guardians, Innate lymphoid cells  Àӹοµ(¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ15:28~15:40 Development of humanized ACE2-expressing mouse model for COVID-19  ¹Ú¿îÀÌ(¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ15:40~15:52 Mutation patterns of SARS-CoV-2 through serial passage in human cell lines  ³ëÁö¿µ(ÃæºÏ´ëÇб³ »ý¸í½Ã½ºÅÛÇаú) 
Åä·Ð 08-27 ´ë°­ÀǽǠ15:52~16:10 ÁúÀÇÀÀ´ä  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2022³â ´ëÇѹÙÀÌ·¯½ºÇÐȸ Á¤±âÇмú´ëȸ : 2022-08-27""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2022³âµµ ´ëÇѽŰæ¿Ü°úÇÐȸ ´ë±¸¡¤°æºÏÁöȸ Á¦3Â÷ ¿¬¼ö±³À° : 2022-08-27
´ÙÀ½±Û 2022 ´ëÇÑ°ñ´ë»çÇÐȸ °ñ¼øȯ ½ÉÆ÷Áö¿ò (The 21st International Symposium of Association Research Circulation Osseous)(2ÀÏÂ÷) : 2022-08-27
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
116 ºÎ»ê 2018³â ´ëÇÑÁßȯÀÚÀÇÇÐȸ ºÎ»ê¿ï»ê°æ³²Áöȸ NIV ¿öÅ©¼¥ : 2018-08-25 0 892 2018-07-28
115 ÀÎõ 2018³â ´ëÇѺҾÈÀÇÇÐȸ Çϰ迬¼ö±³À° : 2018-08-25 0 619 2018-07-28
114 ¼­¿ï Çѱ¹¿©ÀÚÀÇ»çȸ ¿°Áõ¼º Àå Áúȯ Áø´Ü°ú Ä¡·á / ³»½Ã°æ ¹ßÀü ¿ª»ç : 2018-08-25 0 539 2018-07-28
113 ´ë±¸ ´ëÇѵÎÅëÇÐȸ ´ë±¸, °æºÏÁö¿ª º¸¼ö±³À°(¸¸¼ºÆíµÎÅë Áø´Ü ¹× Ä¡·á 6 ´Ü°è) : 2018-08-25 0 757 2018-07-28
112 °æ±â Á¦ 7ȸ ÀÎÁ¦´ëÇб³ ÀÏ»ê¹éº´¿ø Á¤Çü¿Ü°ú ½ÉÆ÷Áö¿ò : 2018-08-25 0 611 2018-07-28
111 ¼­¿ï Á¦2ȸ ´ëÇѼҾÆÁßȯÀÚÀÇÇÐȸ ¼Ò¾Æ±â°èȯ±â ¿öÅ©¼ó ¿ÀÀü session(8.25) : 2018-08-25 0 998 2018-07-28
110 ¼­¿ï Á¦2ȸ ´ëÇѼҾÆÁßȯÀÚÀÇÇÐȸ ¼Ò¾Æ±â°èȯ±â ¿öÅ©¼ó Interactive workshop(8.25) : 2018-08-25 0 700 2018-07-28
109 ±¤ÁÖ ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ Á¦99Â÷ Àü³²ºÏÁöȸ ¿¬¼ö°­Á : 2018-08-25 0 621 2018-07-28
108 ºÎ»ê ´ëÇѽŰæÁßÀçÄ¡·áÀÇÇÐȸ East Asian Conference of Neurointervention 2018 : 2018-08-25 0 255 2018-07-28
107 ¼­¿ï 2018³â Á¦11ȸ ¼­¿ï´ëÇб³º´¿ø ÀçÈ°ÀÇÇаú ¿¬¼ö°­Á : 2018-08-25 0 542 2018-07-28
106 ¼­¿ï 2018³â ´ëÇÑ°©»ó¼±ÇÐȸ Ãß°èÇмú´ëȸ(8/25) : 2018-08-25 0 267 2018-07-28
105 °æ³² ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ 2018 Post Graduate Asthma School (1ÀÏÂ÷) : 2018-08-25 0 412 2018-07-28
104 ÀÎõ Á¦8Â÷ °¡Å縯´ëÇб³ ÀÎõ¼º¸ðº´¿ø È£Èí±â³»°ú ±â°èȯ±â ¿öÅ©¼ó : 2018-08-25 0 1,258 2018-07-28
103 ¼­¿ï ´ëÇѼҾƽŰæÇÐȸ Fellowship in Training : 2018-08-25 0 533 2018-07-28
102 °æ±â Á¦5Â÷ ¾Æ½Ã¾ÆºÎÀÎÁ¾¾çÇÐȸ ¿öÅ©¼ó(ASGO 5th International Workshop on Gynecologic Oncology in conjunction with 12th KSGO Workshop for Young Gynecologic Oncologists) : 2018-08-25 0 329 2018-07-28
1401 | 1402 | 1403 | 1404 | 1405 | 1406 | 1407 | 1408 | 1409 | 1410
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷